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Recurrence Score Assay—a clinically validated prognosticator in stage
II colon cancer after surgical resection—on adjuvant treatment deci-
sions in T3 mismatch repair proﬁcient (MMR-P) stage II colon cancer
in clinical practice. Methods: This retrospective analysis included all
patients with T3 MMR-P stage II colon cancer (Clalit Health Services
members) with Recurrence Score results (time frame January 2011 to
May 2012). Treatment recommendations pretesting were compared
with the treatments received. Changes were categorized as decreased
(to observation alone/removing oxaliplatin from the therapy) or
increased (from observation alone/adding oxaliplatin to the therapy)
intensity. Results: The analysis included 269 patients; 58%, 32%, and
10% of the values were in the low (o30), intermediate (30–40), and
high (Z41) score groups, respectively. In 102 patients (38%), treatment
changed post-testing (decreased/increased intensity 76/26 patients).
The overall impact was decreased chemotherapy use (45.0% to 27.9%;
P o 0.001). Treatment changes occurred in all score groups, but more
frequently in the high (change rate 63.0%; 95% conﬁdence interval [CI]ee front matter Copyright & 2016, International S
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afﬁliated with Sackler School of Medicine, Tel Avi42.3%–80.6%) than in the intermediate (30.6%; 95% CI 21.0%–41.5%)
and low (37.6%; 95% CI 30.0%–45.7%) score groups. The direction
of the change was consistent with the assay result, with increased
intensity more common in higher score values and decreased inten-
sity more common in lower score values. Conclusions: Testing sig-
niﬁcantly affected adjuvant treatment in T3 MMR-P stage II colon
cancer in clinical practice. The study is limited by its design, which
compared treatment recommendations pretesting to actual treat-
ments received post-testing, lack of a control group, and nonassess-
ment of confounding factors that may have affected treatment
decisions.
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Colorectal cancer is the third most common cancer and the
fourth leading cause of cancer death worldwide [1]. Globally,
every year, colon and rectal cancers are diagnosed in 1.4 million
individuals and lead to 700,000 deaths [1]. Approximately one-
quarter of the patients with colon cancer present with stage II
disease [2], in which the role of adjuvant chemotherapy remainscontroversial. In this patient population, the 5-year survival rate
with surgery alone is 70% to 80% [3] and the evidence relating to
the clinical beneﬁt of 5-ﬂuorouracil (5-FU)-based adjuvant che-
motherapy regimens from individual studies and meta-analyses
is inconsistent [4–9]. The current National Comprehensive Cancer
Network guidelines include adjuvant chemotherapy as a treatment
option in this setting, particularly for high-risk stage II patients, as
determined by clinical and pathological parameters [10]. Althoughociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 2 – 8 7 83some of the routinely used parameters for estimating recurrence
risk such as T-stage and mismatch repair (MMR) status are well
established, with T4 patients having higher recurrence risk and
patients with MMR-deﬁcient tumors having lower recurrence risk,
other parameters, including tumor grade and lymphovascular
invasion, may not be reliable predictors of recurrence risk in this
population [11–17]. Most of the patients (75%) with stage II colon
cancer have T3 MMR-proﬁcient (MMR-P) tumors [15], and are
therefore considered standard risk. These patients could therefore
beneﬁt from a tool that would further reﬁne their risk of recurrence
and facilitate individualized adjuvant treatment decisions.
The 12-gene Oncotype DX Colon Cancer Assay (Genomic Health,
Inc., Redwood City, CA) is a reverse transcriptase polymerase chain
reaction–based assay that provides a Recurrence Score (RS) result
[18]. The assay has been clinically validated (level I, category B
evidence [19]) as a predictor of recurrence risk following surgical
resection in patients with both stage II and III colon cancer in three
validation studies [15,16,20]. The validation studies used archived
samples from prospectively designed clinical trials (the Quick and
Simple and Reliable study, the Cancer and Leukemia Group B 9581
study, and the National Surgical Adjuvant Breast and Bowel Project
C-07 study), involving a total of 3018 patients. Together, these studies
demonstrated that in stage II patients, the Recurrence Score result is
an independent predictor of recurrence risk, along with T-stage and
MMR status, and is able to predict the risk of recurrence beyond
traditional clinical and pathological parameters [15,16,20]. Interest-
ingly, a recent study involving 297 patients with stage II/III rectal
cancer who were randomized to surgery alone in the Dutch total
mesorectal excision (TME) trial demonstrated that the Recurrence
Score result can predict recurrence risk in this population as well,
suggesting a similar underlying biology in colon and rectal cancers
[21]. In the United States, the 12-gene colon cancer assay has been
commercially available for patients with stage II and stage III colon
cancer who have undergone surgical resection since January 2010.
In Israel, the assay has been reimbursed by Clalit Health Services
(CHS; the largest health care organization in Israel with more than
4 million members) since January 2011.
Since the introduction of the 12-gene colon cancer assay, two
additional colon cancer genomic assays have become available.
Both of these assays—ColoPrint (Agendia NV, Amsterdam, The
Netherlands) and ColDx assay (Almac Diagnostics, Craigavon,
Northern Ireland)—use microarray technology for assessing the
gene expression of 18 and 634 genes, respectively, and stratify
patients into low and high recurrence risk groups [22–25]. Both
assays have been clinically validated using retrospective cohort
studies (level IIIC or IV evidence [19]).
Following establishment of the clinical validity of a diagnostic
test, ascertaining its clinical utility (i.e., improved measureable
clinical outcomes, usefulness, and added value for clinical deci-
sion making [26]) is key for its incorporation into clinical practice
and ultimately for determining cost-effectiveness. One approach
for determining clinical utility is through decision impact studies.
For the 12-gene colon cancer assay, two such studies were
performed, both in the United States [27–29]; the study reported
herein addresses clinical practices outside the United States.
The aim of this study was to evaluate the impact of the 12-
gene colon cancer assay on treatment decision making for
patients with T3 MMR-P stage II colon cancer in a conventional
clinical practice setting in Israel.Methods
Study Design and Patient Population
This was a preplanned analysis of a prospectively designed
registry. It included all patients with stage II colon cancer (treatedin the seven participating institutions) who underwent the 12-
gene colon cancer assay testing through CHS between January
2011 and May 2012. The analysis was restricted to patients with
T3 MMR-P tumors. The study was approved by the institutional
review board of the CHS as well as the institutional review boards
of the participating institutions (Davidoff Cancer Center,
Hadassah-Hebrew University Medical Center, Kaplan Medical
Center, Lin Medical Center, Rambam Healthcare Campus, Soroka
University Medical Center, and Tel Aviv Sourasky Medical Cen-
ter). All patients signed an informed consent form.Patient Flow and Data Source
Upon enrollment of patients into the registry, the treating
physicians reported information on patients’ baseline character-
istics. Treatment recommendations before testing with the 12-
gene colon cancer assay were speciﬁed by the treating physician
(upon enrollment) using a questionnaire. The same treating
physician reviewed the Recurrence Score results (received within
8–12 days of testing) and made treatment recommendations
post-testing. In patients who received adjuvant chemotherapy,
treatment initiation was typically within 1 week of receiving the
test results. Actual treatments received post-testing were
obtained from retrospective review of the CHS database.Recurrence Score Result Determination
The Recurrence Score result is derived from reference-
normalized gene expression measurements made by quantitative
real-time reverse transcriptase polymerase chain reaction using
RNA extracted from a ﬁxed, parafﬁn-embedded tumor block
obtained by surgical resection. The gene panel used for the assay
comprises 12 genes: 7 cancer-related genes including 3 cell-cycle
genes, 3 stromal genes, and the early response gene, GADD45B,
and 5 reference genes [18]. Stromal group score and cell-cycle
group score are calculated from reference-normalized individual
gene expression measurements, and an unscaled RS (RSu) result
is determined using the following calculation: RSu ¼ (0.15 
Stromal group score)  (0.3  Cell-cycle group score) þ (0.15 
GADD45B). The Recurrence Score result is then rescaled from 0 to
100. Patients are categorized into three risk groups according to
their Recurrence Score result: low (o30), intermediate (30–40),
and high (Z41) [18].Statistical Analysis
Descriptive statistics were used to summarize patient and tumor
characteristics, treatment recommendations before testing with
the 12-gene colon cancer assay, and actual treatments received
after testing. For each patient, the treatment recommendation
pretesting was compared with the actual treatment received
(post-testing). Change in treatment was deﬁned as either a
decreased intensity change if the changes were to observation
alone or to remove oxaliplatin from the adjuvant therapy; or an
increased intensity change if the changes were from observation
alone or to add oxaliplatin to the adjuvant therapy. Changes in
treatment intensity were also evaluated according to the Recur-
rence Score groups, as deﬁned in the Quick and Simple and
Reliable study [15]. The McNemar test was used to assess
whether the difference between the proportion of patients with
chemotherapy recommendations (pretesting) and the proportion
of patients actually receiving chemotherapy (post-testing) was
signiﬁcant. All analyses were conducted using SAS statistical
software version 9.4 (SAS Institute Inc., Cary, NC); P o 0.05 was
considered signiﬁcant.
Table 1 – Patient and tumor characteristics.
Characteristic Value (N ¼ 269)
Age (y)
Median (IQR) 68 (60–75)
Z70 y, n (%) 129 (48.0)
Histologic type, n (%)
Adenocarcinoma 225 (83.6)
Mucinous adenocarcinoma 43 (16.0)
Signet-ring cell carcinoma 1 (0.4)
Grade, n (%)
Low 49 (18.2)
Moderate 195 (72.5)
High 19 (7.1)
Unknown 6 (2.2)
Number of nodes examined
Median (IQR) 17 (13–22)
Z12 229 (85.1)
Obstruction or perforation present, n (%) 43 (16.0)
Lymphovascular invasion present, n (%) 15 (5.6)
Recurrence Score
Median (range) 28 (7–70)
IQR 22–34
Recurrence Score distribution, n (%)
Low (o30) 157 (58.4)
Intermediate (30–40) 85 (31.6)
High (Z41) 27 (10.0)
IQR, interquartile range.
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Study Patients
Between January 2011 and May 2012, 312 patients with T3 stage II
colon cancer underwent testing with the 12-gene colon cancer
assay and MMR testing through the CHS (these patients con-
stitute approximately 60% of the CHS patients with T3 stage II
colon cancer diagnosed in this time frame). Thirty-nine of these
312 patients (12.5%) were found to have MMR-deﬁcient tumors
and were excluded from the present analysis. Of the 273 patients
with MMR-P tumors, 269 patients (98.5%) were included in the
primary analysis. Four patients were excluded: three did not have
pretesting treatment recommendations, and one was excluded
on the basis of pathology/laboratory exclusion criteria.
Patient characteristics were representative of the contemporary
T3 stage II colon cancer patient population [30] (Table 1). The median
Recurrence Score value was 28 (range 7–70), and the interquartile
range was 22 to 34. More than half of the study patients (58.4%) had
Recurrence Score values in the low, approximately one-third (31.6%)Table 2 – Impact of knowing the Recurrence Score result
Pretesting recommendations
Observation
Observation (n ¼ 148) 123 (83.1)†
5-FU only (n ¼ 105) 60 (57.1)
5-FU þ oxaliplatin (n ¼ 16) 11 (68.75)
Total (N ¼ 269) 194 (72.1)
5-FU, 5-ﬂuorouracil.
* For each pretesting recommendation, the table presents the number (a
† Cases with no change between pretesting recommendation and actualin the intermediate, and one-tenth (10.0%) in the high score (Table 1)
groups.
Recurrence Score Results and Treatment Changes
In 102 patients (37.9%; 95% conﬁdence interval [CI] 32.1%–44.0%),
review of the Recurrence Score results by the physician affected
treatment, resulting in a decrease in treatment intensity in 76
patients (28.2%; 95% CI 23.0%–34.0%) and an increase in treatment
intensity in 26 patients (9.7%; 95% CI 6.4–13.8%) (Table 2).
The observed changes in treatment intensity led to a statisti-
cally signiﬁcant change in the proportion of patients treated with
chemotherapy (5-FU or 5-FU plus oxaliplatin; Po 0.001; McNemar
test). The proportion of patients receiving chemotherapy
decreased from 45.0% to 27.9%; observation increased from
55.0% to 72.1% (Fig. 1).
Comparing the distribution of the Recurrence Score results by
treatment (pretesting recommendation vs. post-testing actual
treatment received) showed that the median Recurrence Score
result shifted in all groups. It became lower in the observation
group and higher in the chemotherapy groups (observation
group: from 27 to 26; 5-FU group: from 28 to 34; 5-FU plus
oxaliplatin group: from 28.5 to 41; Fig. 2).
Treatment changes were also analyzed by Recurrence Score
groups. Although changes were noted in all groups, they occurred
more frequently in the high-score group (change rate of 63.0%;
95% CI 42.3%–80.6%) than in the intermediate-score (30.6%; 95% CI
21.0%–41.5%) and low-score (37.6%; 95% CI 30.0%–45.7%) groups
(Table 3). In the high-score group, increased treatment intensity
changes were more common than decreased treatment intensity
changes (40.7% vs. 22.2%), with most of the increased intensity
changes from observation to chemotherapy (90.9%). In contrast,
in the low-score group, decreased intensity changes were more
common (35.0% vs 2.5%), with most of the decreased intensity
changes from 5-FU monotherapy to observation (76.4%). In the
intermediate-score group, the change rates were similar overall
(17.6% and 12.9% for decreased and increased treatment intensity
changes, respectively; Table 3).
In the high-score group, the observed changes in treatment
intensity led to a net increase in chemotherapy use of 18.6%
(from 40.7% to 59.3%), whereas in the low-score group, there was
a net decrease in chemotherapy use of 30.6% (from 44.6% to
14.0%) (Fig. 1).Discussion
In this preplanned study using a prospectively designed registry
in Israel—the ﬁrst study outside the United States and potentially
relevant to European clinical practice—we assessed the impact of
the 12-gene colon cancer assay on patients with T3 MMR-P stage
II colon cancer in real-life clinical practice. We showed that afteron treatments received*.
Actual treatment, n (%)
5-FU only 5-FU þ oxaliplatin
23 (15.5) 2 (1.4)
44 (41.9)† 1 (1.0)
5 (31.25) 0 (0)†
72 (26.8) 3 (1.1)
nd proportion) of patients actually receiving each treatment option.
treatment received.
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* P < 0.001, McNemar’s test; no statistical testing was performed for each of the RS groups. 
Fig. 1 – Impact of the 12-gene colon cancer assay on treatment (pre-testing recommendations vs post-testing actual
treatments). Impact on treatment decisions was assessed for the entire cohort and by Recurrence Score group. For the entire
cohort, a statistically signiﬁcant net reduction in the overall use of chemotherapy was observed (P o 0.001, McNemar’s test);
statistical testing for each of the Recurrence Score groups was not performed. Low score (o 30); intermediate score (30-40); high
score (Z41). *P o 0.001, McNemar test; no statistical testing was performed for each of the RS groups. RS, Recurrence Score.
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actual treatments received differed from pretesting treatment
recommendations in more than one-third of the patients (38%).
Most of the changes resulted in decreased treatment intensity,
and the net result was an overall statistically signiﬁcant decreaseFig. 2 – Distribution of Recurrence Score results by treatment rec
Recurrence Score result shifted in all groups, demonstrating the
horizontal line within each box represents the median. The box
The whiskers represent the 5% to 95% conﬁdence intervals. Ind
(Color version of ﬁgure is available online.)in chemotherapy use of 17%, from 45% to 28%. The direction of
the change was consistent with the assay results, with an
increased intensity treatment change more common in higher
Recurrence Score values and a decreased intensity treatment
change more common in lower score values. Our ﬁndings suggestommendation versus actual treatment received. The median
inﬂuence of the score results on treatment decisions. The
edges represent the lower (25th) and upper (75th) quartiles.
ividual data points were overlaid on the box-whisker plot.
Table 3 – Treatment changes (from pretesting recommendation to actual treatments received after testing) by
Recurrence Score risk group.
Treatment intensity change Recurrence Score risk group, n (%) Total, n (%)
Low
(score result o30)
Intermediate
(score result 30–40)
High
(score result Z41)
Overall
No change 98 (62.4) 59 (69.4) 10 (37.0) 167 (62.1)
Change 59 (37.6) 26 (30.6) 17 (63.0) 102 (37.9)
Increased intensity 4 (2.6) 11 (12.9) 11 (40.8) 26 (9.7)
Decreased intensity 55 (35.0) 15 (17.7) 6 (22.2) 76 (28.3)
Total 157 (100) 85 (100) 27 (100) 269 (100)
Increased treatment intensity
From observation 4 (100.0) 11 (100.0) 10 (90.9) 25 (96.2)
From 5-FU monotherapy 0 (0.0) 0 (0.0) 1 (9.1) 1 (3.8)
Total 4 (100) 11 (100) 11 (100) 26 (100)
Decreased treatment intensity
From 5-FU þ oxaliplatin 13 (23.6) 1 (6.7) 2 (33.3) 16 (21.1)
From 5-FU monotherapy 42 (76.4) 14 (93.3) 4 (66.7) 60 (78.9)
Total 55 (100) 15 (100) 6 (100) 76 (100)
5-FU, 5-ﬂuorouracil.
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in both directions by identifying lower-risk patients who are
expected to gain smaller absolute beneﬁts from chemotherapy
and for whom chemotherapy and its associated toxicities could
be avoided, as well as identifying high-risk patients who are
expected to gain larger absolute beneﬁts from chemotherapy.
The rate of treatment recommendation change observed in our
study is consistent with those of the two US studies in patients
with stage II colon cancer: a retrospective analysis involving 92
evaluable patients of whom 68 had T3 MMR-P tumors and a
prospective study involving 219 patients of whom 141 were
evaluable and had T3 MMR-P tumors. In these studies, a change
in treatment recommendations was observed in 26% and 45% of T3
MMR-P patients, respectively. Consistent with our ﬁndings, in both
these studies, an overall net reduction in adjuvant chemotherapy
recommendation was observed after testing [27–29]. Notably, in
both US studies, the rate of chemotherapy recommendation
pretesting (for all 92 patients in the retrospective study and for
the 141 T3 MMR-P patients in the prospective study) appears to be
higher than that in the present study (52%-57% vs. 45%). A potential
explanation for this difference may be more frequent adjuvant
chemotherapy use in patients with stage II colon cancer in the
United States relative to Europe/Israel as reported in a recent study
comparing population-based registries in the United States and
across Europe [31]. Other explanations include study design and
physician biases in ordering the 12-gene colon cancer assay or in
enrolling patients in decision impact studies.
The net effect of the assay in our study was a reduction in
adjuvant chemotherapy use compared with pretesting recommen-
dations. This reduction could potentially minimize treatment-
related morbidities in patients with T3 MMR-P stage II colon
cancer and is expected to result in cost saving. A health-
economic analysis, performed as a substudy of the prospective
US-based study, demonstrated that treatment decisions based on
incorporation of the 12-gene colon cancer assay would be expected
to result in cost savings for the health care system [32]. A formal
health-economic assessment of the effect of the 12-gene colon
cancer assay in Israel is therefore warranted and underway.
The design of this study facilitated the assessment of the
assay’s impact in a real-life clinical setting. We consider the
present study to constitute an accurate representation of current
treatment trends for this population in Israel: the study includeda large number of patients and physicians from both the
academic and community settings; patient characteristics were
consistent with those of stage IIA patients for whom adjuvant
chemotherapy is considered; and 85% of the patients had 12 or
more lymph nodes examined, indicating a high quality of surgery
and pathology assessments.
The present study compared physicians’ treatment recom-
mendations before receiving the results of the 12-gene colon
cancer assay with actual treatments received (post-testing). The
study has limitations in its design, which lacked a control group,
and in the fact that confounding factors that may have affected
treatment decisions were not assessed (e.g., patients’ preferen-
ces). Furthermore, pretesting recommendations may be inﬂu-
enced by the knowledge that patients will receive an assay result.
Notably, because testing was performed after all the workup has
been completed, the only difference in the information that a
physician had to guide treatment recommendations/decisions
from pretesting to post-testing was the Recurrence Score result.
In conclusion, consistent with previous reported studies in the US
population [27–29], Recurrence Score testing was found to signiﬁ-
cantly affect adjuvant treatment intensity (in both directions) in
patients with T3 MMR-P stage II colon cancer in a real-life clinical
setting that represents European clinical practice. This impact led to
an overall net reduction in chemotherapy use, suggesting that
Recurrence Score testing may lead to improved risk stratiﬁcation
and conﬁdence in risk-adapted use of adjuvant chemotherapy and
consequently to reduced treatment-related complications, as well as
health care expenditures, in this patient population.
Source of ﬁnancial support: Teva Pharmaceutical Industries
Ltd. (the representative of Genomic Health in Israel) funded the
research. Genomic Health, Inc., funded medical writing support
for this manuscript.R E F E R E N C E S[1] Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer
incidence and mortality worldwide: IARC CancerBase No. 11. Available
from: http://globocan.iarc.fr. [Accessed December 14, 2013].
[2] Lee YC, Lee YL, Chuang JP, et al. Differences in survival between colon
and rectal cancer from SEER data. PLoS One 2013;8:e78709.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 2 – 8 7 87[3] Dotan E, Cohen SJ. Challenges in the management of stage II colon
cancer. Semin Oncol 2011;38:511–20.
[4] O’Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy
for stage II colon cancer with poor prognostic features. J Clin Oncol
2011;29:3381–8.
[5] Tournigand C, Andre T, Bonnetain F, et al. Adjuvant therapy with
ﬂuorouracil and oxaliplatin in stage II and elderly patients (between ages
70 and 75 years) with colon cancer: subgroup analyses of the Multicenter
International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the
Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012;30:3353–60.
[6] Yothers G, O’Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant
therapy for colon cancer: updated results of NSABP C-07 trial, including
survival and subset analyses. J Clin Oncol 2011;29:3768–74.
[7] Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant
chemotherapy versus observation in patients with colorectal cancer: a
randomised study. Lancet 2007;370:2020–9.
[8] Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of ﬂuorouracil-
based adjuvant therapy for stage II and III colon cancer: who beneﬁts
and by how much? J Clin Oncol 2004;22:1797–806.
[9] Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant
therapy in colon cancer: observations based on individual patient data
from 20,898 patients on 18 randomized trials. J Clin Oncol
2009;27:872–7.
[10] NCCN clinical practice guidelines for colon cancer version 2.2015 (2015).
Available from: http://www.nccn.org/professionals/physician_gls/pdf/
colon.pdf. [Accessed May 20, 2015].
[11] Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a
predictive marker for lack of efﬁcacy of ﬂuorouracil-based adjuvant
therapy in colon cancer. J Clin Oncol 2010;28:3219–26.
[12] Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability
status as a predictor of beneﬁt from ﬂuorouracil-based adjuvant
chemotherapy for colon cancer. N Engl J Med 2003;349:247–57.
[13] Gunderson LL, Jessup JM, Sargent DJ, et al. Revised TN categorization
for colon cancer based on national survival outcomes data. J Clin Oncol
2010;28:264–71.
[14] Roth AD, Tejpar S, Yan P, et al. Stage-speciﬁc prognostic value of
molecular markers in colon cancer: results of the translational study on
the PETACC 3-EORTC 40993-SAKK 60–00 trial. J Clin Oncol 2009;27
(Suppl): Abstr. 4002.
[15] Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative
multigene reverse transcriptase-polymerase chain reaction assay for
assessment of recurrence risk in patients with stage II colon cancer.
J Clin Oncol 2011;29:4611–9.
[16] Venook AP, Niedzwiecki D, Lopatin M, et al. Biologic determinants of
tumor recurrence in stage II colon cancer: validation study of the 12-
gene recurrence score in Cancer and Leukemia Group B (CALGB) 9581.
J Clin Oncol 2013;31:1775–81.
[17] Harris EI, Lewin DN, Wang HL, et al. Lymphovascular invasion in
colorectal cancer: an interobserver variability study. Am J Surg Pathol
2008;32:1816–21.[18] O’Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor
gene expression and recurrence in four independent studies of patients
with stage II/III colon cancer treated with surgery alone or surgery plus
adjuvant ﬂuorouracil plus leucovorin. J Clin Oncol 2010;28:3937–44.
[19] Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation
of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:
1446–52.
[20] O’Connell M, Lee M, Lopatin M, et al. Validation of the 12-gene colon
cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence
in stage II and III colon cancer patients treated with 5FU/LV (FU) and
5FU/LVþoxaliplatin (FUþOx). J Clin Oncol 2012;30:3512.
[21] Reimers MS, Kuppen PJ, Lee M, et al. Validation of the 12-gene colon
cancer recurrence score as a predictor of recurrence risk in stage II and
III rectal cancer patients. J Natl Cancer Inst 2014;106;106(11). http://dx.
doi.org/10.1093/jnci/dju269.
[22] Salazar R, Roepman P, Capella G, et al. Gene expression signature to
improve prognosis prediction of stage II and III colorectal cancer. J Clin
Oncol 2011;29:17–24.
[23] Kennedy RD, Bylesjo M, Kerr P, et al. Development and independent
validation of a prognostic assay for stage II colon cancer using
formalin-ﬁxed parafﬁn-embedded tissue. J Clin Oncol 2011;29:
4620–6.
[24] Maak M, Simon I, Nitsche U, et al. Independent validation of a
prognostic genomic signature (ColoPrint) for patients with stage II
colon cancer. Ann Surg 2013;257:1053–8.
[25] Kopetz S, Jiang Z-Q, Overman MJ, et al. Genomic classiﬁer (ColoPrint) to
predict outcome and chemotherapy beneﬁt in stage II and III colon
cancer patients. J Clin Oncol 2013;31(Suppl): Abstr. 3612.
[26] Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic
Applications in Practice and Prevention (EGAPP) Initiative: methods of
the EGAPP Working Group. Genet Med 2009;11:3–14.
[27] Cartwright T, Chao C, Lee M, et al. Effect of the 12-gene colon cancer
assay results on adjuvant treatment recommendations in patients with
stage II colon cancer. Curr Med Res Opin 2013;30:321–8.
[28] Srivastava G, Renfro LA, Behrens RJ, et al. Prospective multicenter study
of the impact of oncotype DX colon cancer assay results on treatment
recommendations in stage II colon cancer patients. Oncologist
2014;19:492–7.
[29] You YN, Rustin RB, Sullivan JD. Oncotype DX colon cancer assay for
prediction of recurrence risk in patients with stage II and III colon
cancer: a review of the evidence. Surg Oncol 2015;24:61–6.
[30] Parsons HM, Tuttle TM, Kuntz KM, et al. Association between lymph
node evaluation for colon cancer and node positivity over the past 20
years. JAMA 2011;306:1089–97.
[31] Allemani C, Rachet B, Weir HK, et al. Colorectal cancer survival in the
USA and Europe: a CONCORD high-resolution study. BMJ Open 2013;3:
e003055.
[32] Alberts SR, Yu T, Behrens RJ, et al. Comparative economics of a 12-gene
assay for predicting risk of recurrence in stage II colon cancer.
Pharmacoeconomics 2014;32:1231–43.
